メニュー
Reassesses lipid profile after 5% weight loss in obese patients on pharmacological weight loss therapy to evaluate cardiovascular disease and pancreatitis risk.
デフォルトでは、最初にソースを確認する Prompt が選択されています。直接コマンドに切り替えるか、ローカルコピーをダウンロードすることもできます。
インストールを決める前に、SKILL.md と SkillsMP に表示されている付属ファイルをお読みください。
SOC 職業分類に基づく
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
直接コマンドでは確認用 Prompt が省略されます。実行前にソースを確認してください。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill endo-lipid-reassessment-weight-loss-obesityコマンドは1行のまま表示されます。コピー前に横へスクロールして全体を確認してください。
ローカルで確認しますか？SkillsMP が現在取得できるファイルをダウンロードできます。
SKILL.md を表示中
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
| name | endo-lipid-reassessment-weight-loss-obesity |
| description | Reassesses lipid profile after 5% weight loss in obese patients on pharmacological weight loss therapy to evaluate cardiovascular disease and pancreatitis risk. |
Collect current weight, baseline weight to calculate % weight loss, current weight loss pharmacological therapy, and obtain lipid profile (non-fasting acceptable initially; if triglycerides elevated, repeat fasting). Action: Calculate % weight loss from baseline.
Is % weight loss >=5%?
Interpret lipid levels: triglycerides (normal <150, borderline 150-199, high 200-499, very high >=500 mg/dL) and LDL-C (optimal <100, near optimal 100-129, borderline high 130-159, high 160-189, very high >=190 mg/dL) to assess pancreatitis and ASCVD risk. Action: Stratify risk based on lipid levels.
Use lipid results to update 10-year ASCVD risk (Pooled Cohort Equations) and decide on lipid-lowering therapy per obesity guideline section 5.3: if intermediate/high risk with risk-enhancing factors, consider statin; if triglycerides >=500 mg/dL, address pancreatitis risk. Otherwise, continue current therapy and repeat lipid panel periodically when weight stable.
Do not reassess lipids before 5% weight loss; do not ignore stable weight with <5% loss; do not use non-fasting lipids if triglycerides >500 mg/dL (repeat fasting); consider age/comorbidities when interpreting lipids; do not delay reassessment if weight fluctuates.
45F on liraglutide 3mg daily, lost 8% weight (stable), lipid panel: TC 210, LDL-C 130, HDL-C 45, TG 180 mg/dL.
Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674